Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA.
Future Microbiol. 2019 Jul;14:927-939. doi: 10.2217/fmb-2019-0027. Epub 2019 Jul 23.
Despite the increasing availability of antibiotics with activity against pathogens that cause community-acquired pneumonia (CAP), CAP remains a major cause of morbidity, hospital admissions and re-admissions, and mortality. Lefamulin is a novel pleuromutilin antibiotic with potent activity against both typical and atypical CAP pathogens. In this review of the medical literature, we summarize the available information, including mounting clinical evidence, about lefamulin and its potential value in CAP.
尽管针对引起社区获得性肺炎（CAP）的病原体具有活性的抗生素越来越多，但 CAP 仍然是发病率、住院和再入院以及死亡率的主要原因。Lefamulin 是一种新型截短侧耳素抗生素，对典型和非典型 CAP 病原体均具有强大的活性。在对医学文献的综述中，我们总结了有关 lefamulin 的现有信息，包括不断增加的临床证据，及其在 CAP 中的潜在价值。
